In this regard, some pharmacological inhibitors of AGE formation, such as myriocin [114], and compounds targeting AGE–RAGE signaling, such as sRAGE and RAGE antagonists, have shown promise in reducing AGE-induced maladaptive cardiac hypertrophy and fibrosis. The gene discussed is AGER; the disease is cardiac hypertrophy.